Analyzing Guardant Health (GH) Through an Investor's Lens

By Emilio Sanchez • Tuesday, July 01 10:05 • Permanent Link

Guardant Health logged a -1.0% change during today's morning session, and is now trading at a price of $51.53 per share. The S&P 500 index moved -0.0%. GH's trading volume is 153,036 compared to the stock's average volume of 2,289,700.

Guardant Health trades -13.63% away from its average analyst target price of $59.66 per share. The 22 analysts following the stock have set target prices ranging from $47.0 to $70.0, and on average have given Guardant Health a rating of buy.

If you are considering an investment in GH, you'll want to know the following:

Guardant Health has moved 80.3% over the last year, and the S&P 500 logged a change of 12.6%
Based on its trailing earnings per share of -3.39, Guardant Health has a trailing 12 month Price to Earnings (P/E) ratio of -15.2 while the S&P 500 average is 29.3
GH has a forward P/E ratio of -19.0 based on its forward 12 month price to earnings (EPS) of $-2.71 per share
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally.
Based in Palo Alto, the company has 1,999 full time employees and a market cap of $6.38 Billion.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.